thalidomide has been researched along with Fistula in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Fistula: Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents." | 7.78 | Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. ( Felipez, LM; Gokhale, R; Kirschner, BS; Tierney, MP, 2012) |
| "The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents." | 3.78 | Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. ( Felipez, LM; Gokhale, R; Kirschner, BS; Tierney, MP, 2012) |
| "Thalidomide appears to be an effective and relatively safe drug to maintain response to infliximab in chronically active and fistulizing refractory Crohn's disease." | 2.70 | An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. ( Allez, M; Bonnet, J; Lemann, M; Modigliani, R; Sabate, JM; Villarejo, J, 2002) |
| "Twelve adult male patients with Crohn's Disease Activity Index (CDAI) scores of > or = 250 and < or = 500 despite > or = 20 mg prednisone/day were enrolled." | 2.69 | An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. ( Abreu-Martin, MT; Hassard, PV; Kam, LY; Papadakis, KA; Targan, SR; Vasiliauskas, EA; Yang, H; Zeldis, JB, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Felipez, LM | 1 |
| Gokhale, R | 1 |
| Tierney, MP | 1 |
| Kirschner, BS | 1 |
| Vasiliauskas, EA | 1 |
| Kam, LY | 1 |
| Abreu-Martin, MT | 1 |
| Hassard, PV | 1 |
| Papadakis, KA | 1 |
| Yang, H | 1 |
| Zeldis, JB | 1 |
| Targan, SR | 1 |
| Sabate, JM | 1 |
| Villarejo, J | 1 |
| Lemann, M | 1 |
| Bonnet, J | 1 |
| Allez, M | 1 |
| Modigliani, R | 1 |
2 trials available for thalidomide and Fistula
| Article | Year |
|---|---|
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Crohn Disease; Electromyography; Fi | 1999 |
An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
Topics: Adult; Aged; Antibodies, Monoclonal; Chronic Disease; Crohn Disease; Drug Resistance; Female; Fistul | 2002 |
1 other study available for thalidomide and Fistula
| Article | Year |
|---|---|
Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2012 |